Modality
ERT
MOA
FXIai
Target
JAK1
Pathway
T-cell
UC
Development Pipeline
Preclinical
~Nov 2018
→ ~Feb 2020
Phase 1
May 2020
Phase 1Current
NCT07192032
2,885 pts·UC
2020-05→TBD·Active
2,885 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P1/2
Active
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07192032 | Phase 1/2 | UC | Active | 2885 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 |